Mutations in FGFR 1-3 genes account for various human craniosynostosis syndromes, while dwarfism syndromes have been ascribed exclusively to FGFR 3 mutations. However, the exact role of FGFR 1-3 genes in human skeletal development is not understood. Here we describe the expression pattern of FGFR 1-3 genes during human embryonic and fetal endochondral and membranous ossification. In the limb bud, FGFR 1 and FGFR 2 are initially expressed in the mesenchyme and in epidermal cells, respectively, but FGFR 3 is undetectable. At later stages, FGFR 2 appears as the first marker of prechondrogenic condensations. In the growing long bones, FGFR 1 and FGFR 2 transcripts are restricted to the perichondrium and periosteum, while FGFR 3 is mainly expressed in mature chondrocytes of the cartilage growth plate. Marked FGFR 2 expression is also observed in the periarticular cartilage. Finally, membranous ossification of the skull vault is characterized by co-expression of the FGFR 1-3 genes in preosteoblasts and osteoblasts. In summary, the simultaneous expression of FGFR 1-3 genes in cranial sutures might explain their involvement in craniosynostosis syndromes, whereas the specific expression of FGFR 3 in chondrocytes does correlate with the involvement of FGFR 3 mutations in inherited defective growth of human long bones.
Introduction
The FGF family consists of at least 15 members which are able to bind to and activate four different transmembrane tyrosine kinase receptors FGFRs 1-4 (Basilico and Moscatelli, 1992; Johnson and Williams, 1993; Mason, 1994; Yamasaki et al., 1996; Smallwood et al., 1996; Coulier et al., 1997; McWhirter et al., 1997) . Alternative splicing can generate two principal isoforms of FGFRs 1-3 (IIIb and IIIc) which differ in their affinity for various FGF isoforms (Partanen et al., 1992; Johnson and Williams, 1993; Chellaiah et al., 1994; Wang et al., 1995; McArthur et al., 1995; Ornitz et al., 1996) . Recently, genetic analysis of human skeletal disorders have highlighted the critical role of the FGF-FGFR system in endochondral and endomembranous ossification. Achondroplasia, thanatophoric dysplasia (types I and II), and hypochondroplasia have been ascribed to FGFR 3 mutations producing constitutive activation of the receptor (for review, see Webster and Donoghue, 1997) . FGFR 1-3 mutations also accounted for various craniosynostosis syndromes: Apert, Pfeiffer, Crouzon, Jackson-Weiss, Beare Stevenson syndromes, and coronal craniosynostoses (for reviews, see Webster and Donoghue, 1997; Wilkie, 1997) .
Gene targeting experiments have confirmed the critical role of FGFR 1 in early morphogenesis, as null mice died during early embryogenesis (Deng et al., 1994; Yamagushi et al., 1994) . Similarly, deletion of the third Ig loop domain of Fgfr 2 in mice resulted in premature death at 10-11 days of gestation with no limb bud formation (Xu et al., 1998) .
By contrast, targeted disruption of Fgfr 3 and Fgf 2 overexpression resulted in skeletal malformations with either overgrowth of long bones in Fgfr 3 null mice, or flattened and shortened long bones and macrocephaly in Fgf 2 mutants (Coffin et al., 1995; Colvin et al., 1996; Deng et al., 1996) . Surprisingly, Fgf 2 knock-out mice displayed no skeletal defects (Zhou et al., 1998) .
Extensive expression studies in various species have localized FGFR transcripts in a variety of tissues and organs at different stages of development (Partanen et al., 1991; Orr-Urtreger et al., 1991 , 1993 Peters et al., 1992 Peters et al., , 1993 Patstone et al., 1993; Launay et al., 1994; Wuechner et al., 1996; Gonzalez et al., 1996; Wilke et al., 1997; Matovinovic and Richman, 1997) . While FGFR 1 and FGFR 2 mRNAs have been mainly detected in the perichondrium and periosteum of mouse long bones at day 16.5 post-coitum (Peters et al., 1992) , FGFR 3 transcripts were found in proliferative chondrocytes of the growth plate in newborn mice (Deng et al., 1996) . Recently, expression of FGFR 2 in the mouse skull vault has been reported (Iseki et al., 1997) , but the temporo-spatial pattern of expression of the FGF receptors at different stages of the ossification process both in human and animals remains unknown. Our recent demonstration of discrepancies in FGFR 3 chondrocytic expression between mouse and human fetuses indeed emphasizes the requirement for human developmental studies (Delezoide et al., 1997) .
The present work reports on the differential expression of FGFR 1-3 genes during limb and head ossification process in human embryos and fetuses, from stage Carnegie 12 (26-28 days of development), to late fetal life, and provides new elements for a better understanding of phenotypes related to FGFR mutations.
Results

Endochondral ossification of the limbs
Limb bud initiation (end of the 4th week, Carnegie 12-13)
In human, the upper limb buds appear on day 24 as small bulges on the lateral body wall, at the level of C5 to C8 vertebrae, followed on day 28 by lower limbs bulging at the L3 to L5 level. Each flattened and paddle-shaped bud is formed by a mesenchymal core covered by ectodermal epithelium (Fig. 1A) .
At this stage, the FGFR 1 gene was intensely and uniformly expressed in the mesenchymal core of the limb bud, whereas FGFR 2 expression was only detected in the surrounding epidermis (Fig. 1B,C) . The IIIc and IIIb isoforms of FGFR 3 gave no signal, as compared to labeling with the sense probes (data not shown). Indeed, no significant labeling with the IIIb isoform was found at later stages in skeletal structures.
Proximo-distal growth of the bud (early 5th week, Carnegie 13-14)
Shortly after bulging of the limb bud, the mesoderm induces the overlying epithelium of the tip of the limb to thicken, thus giving rise to the apical ectodermal ridge (AER) which releases signals to the underlying mesenchyme in an avascular region termed the progress zone. In this area, cells remain undifferentiated, and proliferate to allow the proximo-distal growth of the limb bud. At the same time, the proximal bud mesenchyme is invaded by nerve fibers and somitic myogenic cells, but remains morphologically undifferentiated ( Fig. 2A) . At Carnegie 13, the signal obtained with both FGFR 1 and 3 (IIIc) riboprobes in the upper limb bud was diffuse, but FGFR 1 expression was higher than FGFR 3 (IIIc). An intense labeling with the FGFR 2 probe was detectable in epidermal structures, including AER, and appeared in a proximo-dorso-caudal region of the mesenchyme (Fig. 2) . Standard HES staining indicated that FGFR 2 expressing mesenchymal cells were histologically undistinguishable from non expressing cells. In an attempt to further characterize their phenotype, we used (i) cresyl violet (for proteoglycans staining), (ii) anti-type I or type II collagen and anti-PCNA (Proliferating Cell Nuclear Antigen) antibodies, and (iii) in situ hybridization with COL 2A1 and tenascin riboprobes. These procedures failed to distinguish FGFR 2 expressing from non-expressing cells (data not shown), suggesting that they were not yet prechondrogenic condensing cells (Hall and Miyake, 1995) . Similar results were obtained with longitudinal sections of the lower limbs of Carnegie 14 embryos (Fig. 2F) . (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) From Carnegie 15 (33 days), rod-like mesenchymal condensations appear along the long axis of the limb bud (Fig.  3A,E) . At this time, FGFR 1 was uniformly expressed in both the loose and the condensed pre-cartilaginous mesenchyme (Fig. 3B) . By contrast, high FGFR 2 expression was restricted to mesenchymal condensations and to the epidermis (Fig. 3C,F) . Low FGFR 3 (IIIc) mesenchymal labeling was observed (Fig. 3D) .
Limb chondrification
The first chondrification centers in the proximal segment of the upper limb are seen at about 40 days , when mesenchymal cells differentiate into chondrocytes. Secretion of extracellular matrix molecules (mainly collagen type II and aggrecan) results in the formation of cartilaginous anlage of each future bone. At later stages, chondrification progresses towards the distal segment of the limb.
When mesenchymal cells undergo differentiation into mature chondrocytes, they progressively stop expressing FGFR 1 and FGFR 2, which are then restricted to the perichondrium, while significant amount of FGFR 3 (IIIc) transcripts are detected. Interestingly, at the onset of chondrification in mesenchymal condensations, reduced expression of FGFR 2 occurred earlier than FGFR 1, as observed in a 6-week metacarpal anlage ( Fig. 4A-C) : FGFR 2 labeling outlined precartilaginous condensations, while FGFR 1 remained uniformly expressed.
By 44 days, before the onset of ossification, FGFR 3 (IIIc) transcripts appeared to be distributed uniformly in the cartilage tissue (Fig. 4F) . FGFR 1 was weakly detected in the undifferentiated mesenchyme of the limb, but was predominant in the perichondrium. At the cellular level, significant FGFR 1 labeling was noticed in the most external part of epiphyseal cartilage, close to the perichondrium (Fig. 4D ). FGFR 2 mRNA transcripts were only present in the perichondrium and in the epiphyseal chondrocytes of the long bones, with a prominent staining along the future joints ( Fig.  4E ,E′).
Early bone ossification (7th week, from Carnegie 18)
Bone ossification of the upper limb buds begins during the 7th week of development (45 days), when a primary bone collar develops around the future diaphysis of the cartilaginous bone anlage. This collar is formed when mesenchymal cells differentiate into osteoblasts apposing bone matrix along cartilage. Shortly after the onset of ossification, blood vessels invade the cartilaginous diaphyses and central chondrocytes become hypertrophic before undergoing apoptosis (8th week).
At this stage, FGFR 1 and FGFR 2 mRNAs were detected in the collar periosteum and the perichondrium but not in the diaphyseal chondrocytes irrespective of their differentiation status. Labeling of the epiphyseal chondrocytes was the same as in the previous stage (6th week). FGFR 3 (IIIc) expression was maintained in resting and hypertrophic chondrocytes but, unlike FGFR 1 or FGFR 2, no transcripts were observed in the perichondrium or the periosteum (Fig.  5 ).
Endochondral ossification
From week 8, endochondral ossification of the long bones gives rise to diaphyseal ossification and longitudinal growth. At week 11, the different steps of endochondral ossification are visible along the proximo-distal axis of the hand, as evidenced by hybridization with a collagen X riboprobe ( Fig. 6A) .
FGFR 1 was expressed in the perichondrium, the periosteum, the mineralized osseous tissue and in some preosseous cells of the mineralized cartilage (Fig. 6B) . A weak and diffuse signal was observed in the mesenchyme. FGFR 2 transcripts were mostly found in the periarticular cartilage, in the periosteum and to a lesser extent in the perichondrium (Fig. 6D,E ), but not in the cartilage growth plate (not shown). FGFR 3 (IIIc) was preferentially expressed by hypertrophic chondrocytes (Fig. 6C ). Similar observations were made in the long bones (tibiae and femorae) of age-matched fetuses (data not shown). The same specific FGFRs expression pattern was observed in long bones from 15-, 19-, 22-, and 33-week fetuses (Table  1 , Fig. 6F ).
Skull vault ossification
Growing of most facial bones and calvaria is mediated by direct mesenchyme ossification in the presumptive dermis covering the brain.
Head mesenchyme, before ossification
At 6 weeks of development, mesenchymal condensations prefiguring the bone of basicranium become detectable while the skull vault remains unossified (Fig. 7A) .
FGFR 1 expression was marked in the entire head mesenchyme, particularly in the dermis but was less obvious in the vertex and the presumptive meninges (Fig.  7B) . FGFR 2 was strongly expressed in the epidermis, the pre-bone mesenchymal condensations and in the mesenchymal wall of the vault (Fig. 7C) . Low levels of FGFR 3 (IIIc) transcripts were found in the basal head mesenchyme and the epidermis (Fig. 7D) .
Chondrification of the basicranium begins in the 7th week, with the same FGFRs expression pattern as in the limbs (data not shown).
Endomembranous ossification of the skull vault
Endomembranous ossification of the skull vault is initiated during the 8th week of gestation. In the mesenchymal membrane surrounding the brain, proliferative preosteoblasts differentiate into osteoblasts synthesizing the bone matrix. Unmineralized bone matrix (osteoid) deposition starts in six ossification centers simultaneously (two frontal, two parietal, two occipital); then osteo-differentiation progresses radially outwards from these centers. Osteoblasts entrapped in the osteoid are converted into osteocytes while osteoblasts aligned on the outer surface of the osteoid are involved in bone thickening (Fig. 8A,F) . FGFR 1 expression persisted at 8 weeks in the skull vault dermis and in the meninges which failed to be labeled by the FGFR 2 and FGFR 3 probes (Fig. 8) . FGFR 1 and 2 and, to a lesser extent, FGFR 3 genes were markedly expressed in the developing skull vault. At the cellular level, their expression was found in the prebone mesenchyme, prior to osteoblastic secretion of the osteoid (pre-osteoblasts), around the osteoid and the mineralizing bone tissue (osteoblasts). Strong expression of the three receptors also occurred in facial endomembranous bones (Fig. 8) .
Sutures
Later in fetal life, sutures appear at the site of approximation of the ossification centers. Growth of each of the cranial bones progresses radially at the sutural margins whilst osteogenesis occurs at the periosteal surface (Fig. 9A,D,F) .
High expression of FGFR 1 and FGFR 2 genes was observed along the fertile side of the sutures, in the preosseous mesenchymal condensations, the osteoid, and around the bone trabeculae (Fig. 9B,E,G,H) . By contrast, low levels of FGFR 3 (IIIc) transcripts were visible (Fig.  9C,I ). Near the suture, FGFR 1 and 3 (IIIc) expression persisted in osteoblasts located at the periphery of the osseous tissue, in the loose periosteum, whereas FGFR 2 transcripts were also detected in the external fibrous periosteum (Fig. 9 , Table 2 ).
Discussion
To our knowledge, this study is the first to describe the expression of FGFR 1, FGFR 2 and FGFR 3 genes at different stages of bone endochondral and intramembranous ossification in the developing human embryo and fetus. Each FGFR is characterized by distinct spatial and temporal expression patterns that could be related to the involvement of the FGF/FGFR signaling pathway in various cellular processes controlling chondrogenesis and osteogenesis.
Limb formation
Normal development of the appendicular skeleton is likely to involve primarily intermediate mesoderm and interactions of FGF 8 and FGF 10, two members of the FGF family, that would initiate limb bud outgrowth and allow its subsequent patterning (Crossley and Martin, 1995; Crossley et al., 1996; Vogel et al., 1996; Ohuchi et al., 1997) . In the developing limb of the chick embryo, FGF 8 expression is transiently localized in the intermediate mesoderm at the forelimb and hindlimb levels, prior to bud outgrowth. FGF 8 would trigger limb initiation by inducing expression of FGF 10, a secondary factor widely distributed in the lateral plate mesoderm acting on cell (Blunt et al., 1997) , the question is raised whether this low affinity is sufficient to allow limb bud induction. Alternatively, FGF 8 could trigger mesenchymal cell proliferation through direct translocation to their nuclei, in a receptor-independent manner (Wiedlocha et al., 1994) . The specific expression of FGFR 2 in the human ectodermal epithelium further suggests that the 'b' isoform of FGFR 2 (KGFR) represents the epithelial receptor for FGF 10, mediating its paracrine effect on the ectoderm, as FGF 10 only activates the FGFR 2b isoform (Xu et al., 1998) . Once the limb bud is formed, three FGFs namely FGF 8, FGF 4 and FGF 2 are expressed in the apical ectodermal ridge (AER) to sustain limb outgrowth and patterning. More specifically, the combined FGF 4 and 8 activities are able to maintain Shh (Sonic hedgehog) expression in the zone of polarizing activity (ZPA) controlling the formation of the anteroposterior axis (Riddle et al., 1993; Niswander et al., 1993; Vogel et al., 1996) . Since no detectable FGFR overexpression or remarkable pattern was noticed in the presumptive ZPA of human embryos as compared to the surrounding mesenchyme, we speculate that the AERsecreted FGF molecules would uniformly and equally activate mesenchymal cells via FGFR 1 and FGFR 3 (IIIc). Involvement of FGFR 1 and 2 in the epithelio-mesenchymal interactions that regulate limb formation and patterning is further substantiated by clinical features of patients harbouring mutations in the FGFR 1 and FGFR 2 genes. Affected individuals, in addition to craniosynostoses, usually exhibit severe limb defects including syndactylies, synostoses, broad or duplicated thumbs or halluces that are extremely mild or absent in FGFR 3-related craniosynostoses and dwarfism syndromes (Gorlin et al., 1990; Muenke et al., 1997) .
Predominance of FGFR 1 expression in the limb mesenchyme, at the onset of ossification, supports its role in the development of non differentiated tissues (Deng et al., 1994; Yamagushi et al., 1994) .
Bone anlage chondrification
At the onset of mesenchymal condensation and chondrification, FGFR 2 transcripts are restricted to prechondrocytes and become detectable prior to the morphological evidence of cellular proliferation and aggregation, indicating that FGFR 2 is a specific marker of early differentiating chondrogenic cells. It is worth remembering that induction of chondrogenesis in the mouse periotic mesenchyme required the synergistic action of both FGF 2 and TGF b1 on cell differentiation (Frenz et al., 1994) . Similarly, the presence of both FGFs (2, 4, 8) and BMP 2 (a member of the TGF b superfamily secreted by mesenchymal cells of the ZPA) (Hogan, 1996) in the limb bud, suggests that both factors could be involved, via FGFR 2, in the induction of chondrogenesis. At later stages, similarly to mouse skeletogenesis (Orr-Urtreger et al., 1991 , 1993 Peters et al., 1992) , FGFR 1 and 2 expression in prechondrocytes largely exceeded that of FGFR 3 (IIIc) while an opposite situation was noted in mature chondrocytes suggesting that FGFR 1 and FGFR 2 mediate FGF signaling during early chondrogenesis. Although FGF 1 and FGF 2, secreted by chondrocytes, are likely to be involved in chondrogenesis (Cancedda et al., 1995) , additional FGFs, like FGF 9, could play a role in chondrocyte proliferation (Legeai-Mallet et al., 1998) .
Endochondral ossification
During endochondral ossification, resting chondrocytes undergo proliferation, then cease proliferating to mature and become hypertrophic. These hypertrophic cells synthesize specific markers including collagen type X and BMP 6 (Schmid et al., 1990; Kingsley, 1994) , then terminally differentiate to be replaced by bone. In rabbit cartilage, FGF 2 was able to promote chondrocyte proliferation but also inhibited their terminal differentiation (Iwamoto et al., 1991) . In human fetuses, only FGFR 3 (IIIc) expression was detected in the growth plate, but no signal was visible in apoptotic chondrocytes of the mineralized zone. Immunohistochemical detection of the receptor in these cells suggested protein stabilization in the absence of excessive transcriptional activity for FGFR 3 (Delezoide et al., 1997) . These results are at variance with the FGFR 3 expression pattern observed in mouse or chick cartilage as no signal was reported in hypertrophic chondrocytes (Patstone et al., 1993; Peters et al., 1993; Deng et al., 1996) . There- fore, the mechanisms controlling bone growth in human are likely to differ significantly from mice, since cellular anomalies resulting from FGFR 3 mutations mostly occurred in the FGFR 3-positive cells of the hypertrophic cartilage (Su et al., 1997; Delezoide et al., 1997; LegeaiMallet et al., 1998) . FGFR 1 expression was observed in the last mineralized arrays of hypertrophic chondrocytes zone and in the adjacent osteoblasts. This receptor might be regarded as a marker of the osteoblastic lineage while FGFR 3 would be a marker of chondrocytic cells.
Of particular interest was the detection of FGFR 2 transcripts both in epiphyseal chondrocytes lining the joints and in articular cartilage at different stages of fetal development. It is tempting to relate this FGFR 2 expression to the high frequency of synostoses that occur in most FGFR 2-associated craniosynostoses (Apert, Pfeiffer and Jackson-Weiss syndromes) (Wilkie, 1997) . Whether FGFR 2 missense mutations promote apoptosis at the level of articular cavities (Uhthoff, 1990; O'Rahilly, 1985) or accelerate differentiation of stem cells into osteoblasts as in cranial sutures of craniosynostosis syndromes (Iseki et al., 1997) remains unclear.
Long bone lengthening at the growth plate level is associated with periostic ossification inducing diaphyses widening. Consistent with animal studies, FGFR 1 and FGFR 2 were found to be highly expressed in the periosteum and perichondrium, while FGFR 3 was absent from these structures. This might account for bone syndactylies observed exclusively in FGFR 1-and FGFR 2-related craniosynostosis syndromes (Gorlin et al., 1990; Muenke et al., 1997) .
Endomembranous ossification
FGFR 1 and FGFR 2 were found to be precociously and intensely expressed in the mesenchyme of presumptive bones of the skull vault, prior to the onset of ossification. At a later stage, when ossification was elicited, FGFR 1, FGFR 2 and FGFR 3 (IIIc) mRNA transcripts were detected in proliferating pre-osteoblasts and osteoblasts, both at the skull vault and face levels. This is the first illustration of the coexpression of the three receptors in bones undergoing membranous ossification, thus suggesting that FGFR 1, (rectangle) showing the perichondral and periosteoid expression of FGFR 1 and 2 genes (G,H), whereas FGFR-3 was expressed in sphenoidal chondrocytes and periosteoid osteoblasts (I) (df). s, sphenoidal cartilaginous anlage; f, frontal endomembranous bone; mb, maxillary bone. Scale bars: A-E = 1 mm; F-J = 100 mm. FGFR 2 and FGFR 3 are involved in the FGF-induced proliferation of pre-osteoblasts and their differentiation into mature osteoblastic cells. In keeping with this, the finding that mutations in FGFR 1, FGFR 2 and FGFR 3 were associated with coronal craniosynostoses (Muenke and Shell, 1995; Webster and Donoghue, 1997) tends to indicate redundancy in receptor functions during membranous ossification. However, similarity exists between the early and specific expression of FGFR 2 in progenitor stem cells of the external periosteum and prechondrogenic cells. Therefore, early FGFR 2 expression might correlate with the higher severity of the phenotypes caused by FGFR 2 mutations. Recently, FGF 2 was hypothesized to play a key role in osteoblastic differentiation since implantation of FGF 2-soaked beads onto mouse sutures mimicked premature fusion of adjacent bones, like in FGFR 2-related craniosynostoses. Diffusion and interaction of FGF 2 with the FGFR 2 receptor of progenitor stem cells would induce their differentiation into osteoblasts to ensure thickening of flat bones (Iseki et al., 1997 ). Yet, even though FGF 2 is the most abundant factor in the skull vault (Hurley and Florkiewicz, 1996) , it does not seem to be critical for bone development as FGF 2 knock-out mice are morphologically normal (Zhou et al., 1998) . Thus, a possible involvement of FGF 8 and other FGFs acting in concert with FGF 2 cannot be ruled out (McArthur et al., 1995; Crossley et al., 1996) , further supporting the requirement for additional studies.
Experimental procedures
Collection and preparation of tissues
Embryos, fetal cartilage and cranial bones samples were obtained from voluntary or spontaneously terminated pregnancies, following the informed consent of the parents, according to the French Ethical Committee recommendations. Embryos were staged using Carnegie classification (Larsen, 1993) , from stage 10 to stage 20. The gestational ages of fetuses varied from 8 to 35 weeks. Embryos or fetal samples were fixed in 4% paraformaldehyde, then embedded in paraffin and serially sectioned.
Immunohistochemistry
Rabbit polyclonal antibodies (Rockland) raised against human type I and type II collagen respectively, and mouse monoclonal anti-PCNA antibody (Novocastra) were used at a 1/100 dilution. After a 1-h incubation of the sections at room temperature, a streptavidin-biotin complex was added for signal amplification and specific detection was achieved by adding the chromogenic substrate diaminobenzidine. Hematoxylin (10%) was used for counterstaining and negative controls were prepared by omitting the primary antibody.
In situ hybridization conditions
For preparation of human FGFR 1 and FGFR 2 cDNA probes, total RNA from cultured chondrocytes and fibroblasts were reverse transcribed and PCR products were cloned in a pCR3 vector (InVitrogen). The FGFR 1 probe (363 bp) encompassed part of the extracellular and transmembrane domains (nucleotides 957-1320). The FGFR 2 probe (486 bp) was generated by using the set of primers: forward 5′-AAAAGCGGCTCCATGCTG-3′; reverse 5′-CAATCTCTTTGTCCGTGGTGT-3′. It encompassed the Ig II loop, the interloop region and part of the IgIII loop (nt 498-974) and identified both the bek ('c' isoform) and KGFR ('b' isoform) transcripts. Two probes specific for the FGFR 3 IIIb (151 bp) and IIIc (132 bp) alternative transcripts were obtained as previously described (Delezoide et al., 1997) . No discrepancy between the originally reported sequences and probe sequences were found. For preparation of the COL2A1 probe, a 1.4-kb cDNA clone encoding part of the triple helical domain and the C terminal end of the a 1 II collagen chain was kindly provided by F. Ramirez (New York). The probe directed against nt 1-778 of human tenascin-C and encompassing the N-terminal extremity of the protein was kindly provided by Liliane Guicharneau and Marie-Claire Gubler (Inserm U423).
Sense and anti-sense riboprobes were generated using either T7 or SP6 RNA polymerases (Promega) in the presence of [a-35 S]UTP (1200 Ci/mmol; NEN). Labeled probes were purified on Sephadex G50. Hybridization and posthybridization procedures were carried out on serial sections, according to standard protocols. Slides were dehydrated, dipped in Kodak NTB 2 emulsion, and exposed for 8-20 days. After development and counterstaining with methyl green, slides were analyzed by bright-field and dark-field microscopy.
Sense probes, used as negative controls, gave no significant signal (Figs. 2G-I, 6G , 7E, 8E,J, 9J). Delezoide et al. / Mechanisms of Development 77 (1998) 19-30 
